Skip to main navigation
NRx Pharmaceuticals, Inc. homepage
  • Our Company
  • Our Therapeutic Focus
    • Bipolar Depression & Suicidality
    • Chronic Pain
    • Post-Traumatic Stress Disorder
  • Our Science
    • NRX-100/NRX-101
    • Our Clinical Approach
    • Mechanism of Action
    • NMDA & 5HT2A Receptors
    • Publications & Breaking News
    • FDA Designations
  • Pipeline
  • Expanded Access and Right to Try
    • NRX-100
    • NRX-101
  • Investor Relations
    • Analyst Coverage
    • Management Answers to Shareholder Questions
    • cUTI Investor FAQs
    • NRX-100 (Ketamine) Investor FAQs
    • SEC Filings
      • Quarterly Reports
      • Section 16 Filings
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Company Info
      • Management Team
      • Board of Directors
      • Contacts
    • Corporate Governance
      • Board Committees
      • Governance Documents
    • Events
    • Investor FAQs
    • Pipeline
    • Press Releases
    • Broadcast / Media
    • Stock Data
      • Stock Quote & Chart
      • Historical Data
  • Presentation
  • Hope Therapeutics
  • Clinical Trials
  • Contact Us
  • Search

Unsubscribe from all NRx Pharmaceuticals, Inc. email alerts

Unsubscribe from all NRx Pharmaceuticals, Inc. email alerts

Corporate Presentation

Click here to view our corporate presentation or on the image below
Corporate Presentation
IP Portfolio
View Our Pipeline
Contact NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. logo
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • Corporate Presentation
  • Hope Therapeutics
  • Investor Relations
  • Resources & Patient Stories
  • Careers
  • Contact Us
  • NRx on Twitter (Opens in new tab)
  • NRx on Linkedin (Opens in new tab)
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use

  • © 2026 NRx Pharmaceuticals, Inc.

  • NRx on Twitter (Opens in new tab)
  • NRx on Linkedin (Opens in new tab)